Nintedanib - Nintedanib/Docetaxel - Nintedanib/DepDocetaxel, page-26

For what it might be worth, just those in this calendar year (and most before the usual AGM date):

1. Announcement of the date of release of Fleurstat to the local market - by July 31st 2018
2. Release of Fleurstat by Aspen - by Sep 30th 2018.
3. Announcement of first local approvals for a Betadine product - by Dec 2018.
4. Announcement of licensing agreements for Europe - by Sep 30th 2018.
5. Announcement of shipments of Vivagel product for Chinese condoms - by Dec 2018.
6. Announcement of FDA decision - by October 31st 2018.
7. Announcement of North American license - by November 30th 2018 (assuming any deal was conditional on FDA approval).
8. Completion of Phase 2 recruitment for DEP Docetaxel - by Dec 31st 2018.
9. Commencement of Phase 1 for DEP Irinetocan - by Nov 30th 2018.
10. Completion of recruitment for Phase 1 - Cabazitaxel - by Oct 31st 2018.
11. Some announcement about viral conjuntivitis - by Dec 31st 2018.
12. Initial AZ takeover offer - before Oct 31st 2018.

Some will think my dates for the DEP trials are optimistic but I base these on the fact that DEP Docetaxel now has a following in the London teaching hospitals and anyone who might be facing non DEP versions of the drugs might be better off with a DEP version. Medical practitioners would be aware of this.

I have no idea why Aspen has been so quiet. The recent advertising approval was for Starpharma and it may have been the case that each thought this was the other's responsibility. I will be asking what the performance conditions were for the Aspen license (if any) and whether these were met.

My date for an AZ offer is based on the supposition that they will want to get in before the price goes ballistic.